相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel
P. Hoskins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO
Jacobus Pfisterer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
A du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
GJS Rustin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
P Royston et al.
STATISTICS IN MEDICINE (2002)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)